Occutrack Medical Solutions is developing a novel mobile Automatic Visual Impairment Detection System (AVIGA) for the management of central vision deterioration. Occutrack’s AVIGA system utilizes advanced gaze-tracking algorithms designed to provide a comprehensive and intelligent assessment of an individual’s vision performance non-invasively in the comfort of their own home without the need for manual or skilled intervention. Consistent monitoring and timely treatment of an individual suffering from AMD can stop and prevent further deterioration of central vision loss, thus improving the quality of life.
The World Health Organization (WHO) estimates that a total of 285 million people worldwide will be visually impaired (2010), of which 39 million are blind and 246 million will suffer from low vision. One of the most common age-related eye diseases that lead to visual impairment is Age-related Macular Degeneration (AMD). AMD is a major cause of central vision loss in people aged 50 and above. It is projected that with the rapidly aging population, there will be a significant increase in the number of people with AMD from 2020 (196 million) to 2040 (288 million). This presents an addressable global market of USD $108 billion.